Medicines and Healthcare products Regulatory Agency

MANUFACTURER'S AUTHORISATION

1: Authorisation Number UK MIA(IMP) 20377

2: Name of authorisation holder ALMAC CLINICAL SERVICES LIMITED

ALMAC CLINICAL SERVICES LIMITED, SEAGOE INDUSTRIAL 3: Address(es) of manufacturing site(s)

ESTATE, 9 CHARLESTOWN ROAD, CRAIGAVON, NORTHERN

IRELAND, BT63 5PW, UNITED KINGDOM

ALMAC CLINICAL SERVICES LIMITED, SEAGOE INDUSTRIAL

ESTATE, 9 CHARLESTOWN ROAD, CRAIGAVON, NORTHERN

IRELAND, BT63 5PW, UNITED KINGDOM

5: Scope of authorisation and dosage forms ANNEX 1 and/ or ANNEX 2

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 6: Legal Basis of authorisation

2004 [SI 2004/1031]

7: Name of responsible officer of the competent authority

4: Legally registered address of authorisation holder

of the member state granting the manufacturing

authorisation

Confidential

8: Authorisation Date 03/05/2024

9: Annexes attached Annex 1 and/or Annex 2

SCOPE OF AUTHORISATION

Annex 2

Name and address of the site:

ALMAC CLINICAL SERVICES LIMITED, SEAGOE INDUSTRIAL ESTATE, 9 CHARLESTOWN ROAD, CRAIGAVON, NORTHERN IRELAND, BT63 5PW, UNITED KINGDOM

Human Investigational Medicinal Products

Authorised Operations

MANUFACTURING OPERATIONS (according to part 1)

IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)

Part 1 - MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.3] Batch certification

[1.2] Non-sterile investigational medicinal products

[1.2.1] Non-Sterile Products (processing operations for the following dosage forms)

[1.2.1.1] Capsules, hard shell

Issue Date: 03 May 2024

[1.2.1.8] Other solid dosage forms [1.2.1.15] Other non-sterile medicinal products Other solid dosage forms - Placebo Powders blistered for inhalers. Capsules, hard shell includes penicillins, hormones and cytotoxics/Capsules soft shell [1.2.2] Batch certification [1.3] Biological investigational medicinal products [1.3.2] Batch certification [1.3.2.1] Blood products [1.3.2.2] Immunological products [1.3.2.3] Cell therapy products [1.3.2.4] Gene therapy products [1.3.2.5] Biotechnology products [1.3.2.6] Human or animal extracted products [1.4] Other investigational medicinal products or manufacturing activitiy [1.4.1] Manufacture of: [1.4.1.1] Herbal products [1.4.1.2] Homoeopathic products [1.4.1.3] Other Importation of QP certified IMPs from a country on the approved country for import list / Herbal products, Homeopathic products, Products authorised under regulation 174 (supply in response to spread of pathogenic agents etc) **Special Requirements** None [1.5] Packaging [1.5.1] Primary packaging [1.5.1.1] Capsules, hard shell [1.5.1.2] Capsules, soft shell [1.5.1.8] Other solid dosage forms [1.5.1.12] Suppositories [1.5.1.13] Tablets [1.5.1.15] Other non-sterile medicinal products Placebo powders blistered for inhalers/Capsules, hard shell, Capsules, soft shell and tablets includes penicillins, hormones and cytotoxics [1.5.2] Secondary packaging [1.6] Quality control testing [1.6.3] Chemical/Physical Part 2 - IMPORTATION OF MEDICINAL PRODUCTS [2.1] Quality control testing of imported medicinal products [2.1.3] Chemical/Physical [2.2] Batch certification of imported medicinal products [2.2.1] Sterile Products

[2.2.1.1] Aseptically prepared

[2.2.1.2] Terminally sterilised

[2.2.2] Non-sterile products

[2.2.3] Biological medicinal products

[2.2.3.1] Blood products

[2.2.3.2] Immunological products

Issue Date: 03 May 2024

- [2.2.3.3] Cell therapy products
- [2.2.3.4] Gene therapy products
- [2.2.3.5] Biotechnology products
- [2.2.3.6] Human or animal extracted products

[2.3] Other Importation Activities

- [2.3.1] Site of Physical Importation
- [2.3.2] Importation of Intermediate which undergoes further processing
- [2.3.3] Biological Active Substance
- [2.3.4] Other

Importation of QP certified IMPs from a country on the approved country for import list / Herbal products, Homeopathic products, Products authorised under regulation 174 (supply in response to spread of pathogenic agents etc)



Manufacturer's Authorisation: UK MIA(IMP) 20377

Page 3 of 3

Issue Date: 03 May 2024